A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: marks (231), grades (548)

Pembrolizumab Ver 1 skin

Description
Chemotherapy Protocol SKIN CANCER Pembrolizumab Pembrolizumab is currently available on a compassionate use basis only – not yet licensed in the UK Regime
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/SkinPembrolizumabVer1.pdf

Nivolumab Ver 1.1 skin

Description
Chemotherapy Protocol SKIN CANCER Nivolumab This regimen may require funding. Regimen Skin – Nivolumab Indication The treatment of advanced (unresectable
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/NivolumabVer1.1.pdf

Nivolumab 480mg skin

Description
Chemotherapy Protocol SKIN CANCER Nivolumab (480mg-28 days) Regimen • Skin – Nivolumab (480mg-28 days) Indication • Nivolumab is recommended, within its m
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Nivolumab-480mg.pdf

Nivolumab 240mg skin

Description
Chemotherapy Protocol SKIN CANCER Nivolumab (240mg-14 days) Regimen • Skin – Nivolumab (240mg-14 days) Indication • Nivolumab is recommended, within its m
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Nivolumab-240mg.pdf

Pembrolizumab (200mg)

Description
Regimen Chemotherapy Protocol HEAD AND NECK CANCER Pembrolizumab (200mg) • Head and Neck – Pembrolizumab (200mg) Indication • Pembrolizumab is recommended
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Pembrolizumab-200mg.pdf

Nivolumab_240mg

Description
Chemotherapy Protocol HEAD AND NECK CANCER Nivolumab (240mg-14 days) Regimen • Head and Neck – Nivolumab (240mg-14 days) Indication • The treatment of rec
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Nivolumab-240mg.pdf

Nivolumab

Description
Chemotherapy Protocol HEAD AND NECK CANCER Nivolumab Regimen • Head and Neck – Nivolumab Indication • The treatment of recurrent or metastatic squamous ce
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Nivolumab.pdf

Pembrolizumab (400mg) head and neck

Description
Chemotherapy Protocol HEAD AND NECK CANCER Pembrolizumab (400mg) Regimen • Head and Neck – Pembrolizumab (400mg) Indication • Pembrolizumab is recommended
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Pembrolizumab-400mg-head-and-neck.pdf

Eisenmenger syndrome - patient information

Description
Eisenmenger syndrome is a form of congenital heart disease in which the pressure in the pulmonary (lung) arteries is high, causing
Url
/Media/UHS-website-2019/Patientinformation/Heartandlungs/Eisenmenger-syndrome-1579-PIL.pdf

Pembrolizumab(400mg)

Description
Chemotherapy Protocol COLORECTAL CANCER Pembrolizumab (400mg) Regimen • Colorectal – Pembrolizumab (400mg) Indication • Pembrolizumab is recommended in in
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/Pembrolizumab400mg.pdf
321 to 330 of 1000
Previous … 31 32 33 34 35 … Next